Direct inhibition of hypoxia-inducible transcription factor complex with designed dimeric epidithiodiketopiperazine.

Selective blockade of hypoxia-inducible gene expression by designed small molecules would prove valuable in suppressing tumor angiogenesis, metastasis and altered energy metabolism. We report the design, synthesis, and biological evaluation of a dimeric epidithiodiketopiperazine (ETP) small molecule transcriptional antagonist targeting the interaction of the p300/CBP coactivator with the transcription factor HIF-1alpha. Our results indicate that disrupting this interaction results in rapid downregulation of hypoxia-inducible genes critical for cancer progression. The observed effects are compound-specific and dose-dependent. Controlling gene expression with designed small molecules targeting the transcription factor-coactivator interface may represent a new approach for arresting tumor growth.

[1]  B. Olenyuk,et al.  Molecular Solids from Symmetrical Bis(piperazine-2,5-diones) with Open and Closed Monomer Conformations. , 2009, Crystal growth & design.

[2]  Justin Kim,et al.  Total Synthesis of (+)-11,11'-Dideoxyverticillin A , 2009, Science.

[3]  P. Dervan,et al.  Modulating hypoxia-inducible transcription by disrupting the HIF-1-DNA interface. , 2007, ACS chemical biology.

[4]  M. Hendrix,et al.  Paradoxical roles for lysyl oxidases in cancer—A prospect , 2007, Journal of cellular biochemistry.

[5]  R. Johnson,et al.  Hypoxia: A key regulator of angiogenesis in cancer , 2007, Cancer and Metastasis Reviews.

[6]  A. Mobasheri,et al.  Hypoxic Regulation of Glucose Transport, Anaerobic Metabolism and Angiogenesis in Cancer: Novel Pathways and Targets for Anticancer Therapeutics , 2007, Chemotherapy.

[7]  P. Dervan,et al.  Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide , 2007, Proceedings of the National Academy of Sciences.

[8]  R. Roskoski,et al.  Vascular endothelial growth factor (VEGF) signaling in tumor progression. , 2007, Critical reviews in oncology/hematology.

[9]  P. Vaupel,et al.  Hypoxia in cancer: significance and impact on clinical outcome , 2007, Cancer and Metastasis Reviews.

[10]  K. Bible,et al.  Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress. , 2007, Blood.

[11]  H. Dvorak,et al.  VEGF-A and the induction of pathological angiogenesis. , 2007, Annual review of pathology.

[12]  R. Johnson,et al.  Hypoxia-Inducible Factor-1α Is a Key Regulator of Metastasis in a Transgenic Model of Cancer Initiation and Progression , 2007 .

[13]  Chi V Dang,et al.  Cancer's molecular sweet tooth and the Warburg effect. , 2006, Cancer research.

[14]  H. Pelicano,et al.  Glycolysis inhibition for anticancer treatment , 2006, Oncogene.

[15]  P. Dervan,et al.  Programmable oligomers for minor groove DNA recognition. , 2006, Journal of the American Chemical Society.

[16]  Hans‐Dieter Arndt.  Small molecule modulators of transcription. , 2006, Angewandte Chemie.

[17]  Quynh-Thu Le,et al.  Lysyl oxidase is essential for hypoxia-induced metastasis , 2006, Nature.

[18]  W. Kaelin,et al.  The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing. , 2005, Biochemical and biophysical research communications.

[19]  Miguel A Esteban,et al.  HIF, a missing link between metabolism and cancer , 2005, Nature Medicine.

[20]  D. Gardiner,et al.  The epipolythiodioxopiperazine (ETP) class of fungal toxins: distribution, mode of action, functions and biosynthesis. , 2005 .

[21]  J. Klco,et al.  Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Gerhard Wagner,et al.  A general framework for development and data analysis of competitive high-throughput screens for small-molecule inhibitors of protein-protein interactions by fluorescence polarization. , 2004, Biochemistry.

[23]  R. Gillies,et al.  Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.

[24]  D. Livingston,et al.  Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. , 2004, Cancer cell.

[25]  C. Chai,et al.  A Novel Redox Mechanism for the Glutathione-dependent Reversible Uptake of a Fungal Toxin in Cells* , 2003, Journal of Biological Chemistry.

[26]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[27]  Gerhard Wagner,et al.  Structural basis for negative regulation of hypoxia-inducible factor-1α by CITED2 , 2003, Nature Structural Biology.

[28]  R. Kelly,et al.  Harnessing the response to tissue hypoxia: HIF-1 alpha and therapeutic angiogenesis. , 2002, Trends in cardiovascular medicine.

[29]  J. Darnell.  Transcription factors as targets for cancer therapy , 2002, Nature Reviews Cancer.

[30]  H. Dyson,et al.  Structural basis for Hif-1α/CBP recognition in the cellular hypoxic response , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D. Livingston,et al.  Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1α , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R. Goodman,et al.  CREB-binding Protein and p300 in Transcriptional Regulation* , 2001, The Journal of Biological Chemistry.

[33]  L. Huang,et al.  Molecular mechanism of hypoxia-inducible factor 1alpha -p300 interaction. A leucine-rich interface regulated by a single cysteine. , 2001, The Journal of biological chemistry.

[34]  Andrew L. Kung,et al.  Suppression of tumor growth through disruption of hypoxia-inducible transcription , 2000, Nature Medicine.

[35]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[36]  J. Mackay,et al.  The Transactivation Domain within Cysteine/Histidine-rich Region 1 of CBP Comprises Two Novel Zinc-binding Modules* , 2000, The Journal of Biological Chemistry.

[37]  A. Giaccia,et al.  Development of a hypoxia-responsive vector for tumor-specific gene therapy , 2000, Gene Therapy.

[38]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[39]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[40]  M. Hiraoka,et al.  Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes. , 1998, International journal of radiation oncology, biology, physics.

[41]  S. Nakatsuka,et al.  Total synthesis of gliotoxin, dehydrogliotoxin and hyalodendrin , 1981 .

[42]  K. Kivirikko,et al.  Mechanism of the prolyl hydroxylase reaction. 2. Kinetic analysis of the reaction sequence. , 1977, European journal of biochemistry.

[43]  H. Weber,et al.  [Isolation and configuration of Chaetocin]. , 1970, Helvetica chimica acta.

[44]  S. Waksman,et al.  Chaetomin, a New Antibiotic Substance Produced by Chaetomium cochliodes , 1944, Journal of bacteriology.